Skip to main navigation
TCR² Therapeutics
  • Our Science
  • Our Pipeline
  • Patients
    • Clinical Trials
    • Expanded Access Program
  • About Us
  • Investors & Media
    • Overview
    • Presentations
    • Stock Information
    • Press Releases
    • Corporate Governance
    • Analyst Coverage
    • Events
    • SEC Filings
    • FAQs
  • Get in Touch
  • Join Us
  • Home
  • Our Science
  • Our Pipeline
  • Patients
    ►
      ◄ Back
    • Clinical Trials
    • Expanded Access Program
  • About Us
  • Investors & Media
    ►
      ◄ Back
    • Overview
    • Press Releases
    • Events
    • Presentations
    • Corporate Governance
    • SEC Filings
    • Stock Information
    • Analyst Coverage
    • FAQs
  • Get in Touch
  • Join Us

Investors & Media

American Association for Cancer Research (AACR) Virtual Annual Meeting

Apr 10 - Apr 15, 2021

For details, please view the press release.

Supporting Materials

Engineering Off-the-shelf T Cell Receptor Fusion Construct (TRuC) T Cells Targeting Mesothelin 3.9 MB
Discovery and Preclinical Characterization of Fratricide-resistant TRuC-T Cells Targeting CD70 723.4 KB
Preliminary Safety and Efficacy of gavocabtagene autoleucel (gavo-cel, TC-210), a T Cell Receptor Fusion Construct (TRuC®), in Patients with Treatment Refractory Mesothelin Overexpressing Solid Tumors 3.1 MB
Preliminary Safety and Efficacy of gavocabtagene autoleucel (gavo-cel, TC-210),…
Discovery and Preclinical Characterization of Fratricide-resistant TRuC-T Cells…
Engineering Off-the-shelf T Cell Receptor Fusion Construct (TRuC) T Cells Targe…

Tools

  • Print Page
  • RSS Feeds
  • Email Alerts
  • Contact IR
  • Our Science
  • Our Pipeline
  • Patients
  • About Us
  • Investors & Media
  • Get in Touch
  • Join Us

© 2023 TCR² Therapeutics. All rights reserved.

TCR² Therapeutics